Novo Nordisk Sues Apotex Over Alleged Patent Infringement on Diabetes Drug Rybelsus

Novo Nordisk Inc., a renowned pharmaceutical company, has initiated legal action against Apotex, accusing the Canadian generic drug giant of infringing on U.S. patents related to Rybelsus. Rybelsus is a prominent medication prescribed for managing Type 2 diabetes and also utilized for weight loss. In the lawsuit filed in a federal court, Novo Nordisk claimed that Apotex’s actions constitute a breach of its patent rights. For more information on this developing case, visit the detailed report on Law360.